About NAD-capped RNA hydrolase NUDT12
NAD-capped RNA hydrolase NUDT12 (NUDT12) is a protein
from Homo sapiens identified by UniProt accession
Q9BQG2, 462 residues long.
MolForge cross-references it against 0 known binders and
28 disease associations.
Target properties
| Protein name | NAD-capped RNA hydrolase NUDT12 |
| UniProt accession | Q9BQG2 |
| Gene | NUDT12 |
| Organism | Homo sapiens |
| Length | 462 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (28)
Diseases linked to this target (Open Targets).
- refractive error measurement · score 0.27
- brain measurement · score 0.27
- risk-taking behaviour · score 0.23
- sporadic amyotrophic lateral sclerosis · score 0.20
- self reported educational attainment · score 0.16
- PHF-tau measurement · score 0.15
- BMI-adjusted waist circumference · score 0.13
- rheumatoid arthritis · score 0.07
- type 2 diabetes mellitus · score 0.03
- intelligence · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BQG2-F1 | alphafold | PREDICTED | 87.42 | — |
Amino-acid sequence (462 residues)
MSSVKRSLKQ EIVTQFHCSA AEGDIAKLTG ILSHSPSLLN ETSENGWTAL MYAARNGHPE IVQFLLEKGC DRSIVNKSRQ TALDIAVFWG YKHIANLLAT AKGGKKPWFL TNEVEECENY FSKTLLDRKS EKRNNSDWLL AKESHPATVF ILFSDLNPLV TLGGNKESFQ QPEVRLCQLN YTDIKDYLAQ PEKITLIFLG VELEIKDKLL NYAGEVPREE EDGLVAWFAL GIDPIAAEEF KQRHENCYFL HPPMPALLQL KEKEAGVVAQ ARSVLAWHSR YKFCPTCGNA TKIEEGGYKR LCLKEDCPSL NGVHNTSYPR VDPVVIMQVI HPDGTKCLLG RQKRFPPGMF TCLAGFIEPG ETIEDAVRRE VEEESGVKVG HVQYVACQPW PMPSSLMIGC LALAVSTEIK VDKNEIEDAR WFTREQVLDV LTKGKQQAFF VPPSRAIAHQ LIKHWIRINP NL
Explore NAD-capped RNA hydrolase NUDT12 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets